Insulin status and adjustment in type 2 diabetic patients' treatment;Place et modalités de l'insulinothérapie chez le diabétique de type 2

Revue de Medecine Interne

Volumn 22, Issue 3, 2001, Pages 265-273

  Bosquet, F ^a   Heurtier, A ^a   Chastang, N ^a   Jacqueminet, S ^a  

^a Section of Radiology   (France)

Author keywords

Bedtime NPH insulin; Combined therapy; Insulin therapy; Oral hypoglycemic drugs; Type 2 diabetes; Weight gain

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFANILAMIDE;

ARTICLE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RISK; WEIGHT GAIN;

EID: 0035100313     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0248-8663(00)00327-1     Document Type: Article

References (65)

1. Physiopathologie du diabète non insulinodépendant
2. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
3. Sustained improvement of glycemic control by insulin treatment after 9 years in patients with type 2 diabetes and secondary failure
4. Quel est le nombre de diabétiques en France?
5. Quels sont les schémas insuliniques utilisés en France?
6. Secondary failure to treatment with oral antidiabetic agents in non insulin dependent diabetes
7. Prognosis factors for successfull insulin therapy in subjects with type 2 diabetes
8. Start of insulin therapy in type 2 diabetic patients
9. Traitement médicamenteux du diabète de type 2
10. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: The Paris prospective study, ten years later
11. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value over 9.5 year-follow up of the Helsinki policemen study population
12. Insulin and atheroma: 20-yr perspective
13. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes
14. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Application, benefits and risks
15. Insulin use in NIDDM
16. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy
17. Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM
18. Comparison of insulin regimens in patients with non insulin dependent diabetes mellitus
19. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas
20. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo out patient trial
21. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus
22. Composition of insulin induced body weight gain in diabetic patients: A bio-impedance study
23. Bed-time insulin/day time glipizide. Effective therapy for sulfonylurea failure in NIDDM
24. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes melitus. A randomized, double-blind, placebo-controlled trial
25. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin dependant diabetes mellitus: A randomized prospective 6-year study
26. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
27. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM)
28. Effect of intensive treatment of diabetes on the risk of death or renal failure in NIDDM and IDDM
29. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
30. Hyperglycemia as an inducer as well a consequence of impaired islet cell function and insulin resistance
31. Remission of insulin requirement in late secondary failure to oral hypoglycemic agents: Results at 24 months and analysis of predictive factors
32. Short term intensive insulin therapy in insulin requiring diabetes: Effectiveness and factors predicting success
33. Rationale for the cure of insulin therapy alone as the pharmacological treatment of type 2 diabetes
34. Is combination sulfonylurea and insulin therapy useful in NIDDM patients?
35. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes
36. The combination of insulin and oral hypoglycemic drugs: A continuous challenge
37. Efficacy of bed-time NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects
38. Sulfonylurea failure in type 2 diabetes: Treatment with a basal insulin supplement
39. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycemic agents
40. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure
41. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes
42. Comparison of bed time NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure
43. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy
44. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone
45. The efficacy of repaglinide administered in combination with bed time NPH insulin in patients with type 2 diabetes
46. Metformin for obese, insulin treated diabetic patients: Improvement in glycemic control and reduction of metabolic risk factors
47. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: An open label randomized trial
48. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
49. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type 2 diabetes
50. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes
51. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM
52. Troglitazone use in insulin-treated type 2 diabetic patients
53. Effect of troglitazone in insulin treated patients with type 2 diabetes mellitus
54. Long term experience with troglitazone in combination with insulin in type 2 diabetes mellitus
55. Comparison of bed-time insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial
56. Efficacy of bed-time NPH insulin alone as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents
57. Comparison of different insulin regimens in elderly patients with NIDDM
58. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects
59. Implantable insulin pump vs multiple dose insulin for non insulin dependent diabetes mellitus: A randomized clinical trial
60. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non insulin dependent diabetes mellitus. Multicenter insulin lispro study group
61. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin dependent or non insulin dependent diabetes mellitus
62. Lispro mix 25 insulin as premeal therapy in type 2 diabetic patients
63. Human insulin analog is comparable to human insulin in type 2 diabetes
64. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: Comparative efficiency and cost of outpatient and impatient management
65. Should insulin therapy in type 2 diabetic patients be started on an out-or inpatient basis? Results of a prospective controlled trial using the same treatment and teaching programme in ambulary care and as university hospital